Who
Yvonne Greenstreet
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Alnylam Pharmaceuticals; Director, Pacira BioSciences; Director, Moelis &; Director, Molecular Insight Pharmaceuticals.
In numbers
- Trades disclosed
- 410
- Buys
- 0
- Sells
- 33
- Bought
- $0
- Sold
- $104.2M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 22 Sep 2008
- Last trade
- 19 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Sep 2026filed 22 Sep 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —107 at $0.00 | filing |
| 19 Sep 2026filed 22 Sep 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —107 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $43K135 at $319.03 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K129 at $320.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $88K274 at $320.81 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $118K368 at $321.82 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $143K444 at $323.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $315K973 at $323.84 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $112K345 at $324.88 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $86K265 at $325.67 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $43K135 at $319.03 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K129 at $320.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $88K274 at $320.81 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $118K368 at $321.82 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $143K444 at $323.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $315K973 at $323.84 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $112K345 at $324.88 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $86K265 at $325.67 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —13,844 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $132K399 at $331.93 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Yvonne Greenstreet; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.